Boosted LLC and Owner Cory Vigil Receive Permanent Injunction from FDA and DOJ

Regulations by 2FIRSTS.ai
Jun.17.2024
Boosted LLC and Owner Cory Vigil Receive Permanent Injunction from FDA and DOJ
Boosted LLC and owner Cory Vigil face permanent injunction for violating FD&C Act by selling unauthorized tobacco products.

The U.S. Food and Drug Administration (FDA) announced on its official website on June 14th that the Federal District Court of Colorado has issued a permanent injunction against Boosted LLC (dba Boosted E-Juice, Boosted, Live Boosted) and its owner Cory Vigil. The ruling prohibits them from manufacturing, selling, or distributing any new tobacco products unless they meet certain requirements.

 

According to a lawsuit filed by the US Department of Justice (DOJ) on behalf of the FDA, the defendant has been warned for serious violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act) regarding pre-market review requirements for new tobacco products, as they did not obtain market authorization from the FDA before selling them. The FDA has warned that continued violations may lead to further legal action, including injunctions.

 

In order to avoid litigation, the defendant signed a consent judgment, which is a written agreement signed by a federal judge and issued as a court order. According to the consent judgment, the defendant agreed not to manufacture, sell, or distribute any new tobacco products until certain requirements are met. These requirements include obtaining FDA marketing authorization for the new tobacco products, FDA inspecting the defendant's facilities to determine compliance with the law, and FDA notifying the defendant in writing that they appear to be in compliance with the law.

 

The FDA and the Department of Justice have initiated an injunction for the eighth time, beginning in October 2022, in order to enforce pre-market review requirements for new tobacco products. The Department of Justice has taken legal action in court under the Federal Food, Drug, and Cosmetic Act. Therefore, on behalf of the FDA, the Department of Justice filed consent decrees for permanent injunction against defendants in the district of Colorado (each manufacturer's respective U.S. District Court).

 

FDA Center for Tobacco Products (CTP) Director Brian King stated:

 

The FDA consistently and resolutely enforces the law, especially after issuing clear warnings and explaining what companies need to do to comply. Those who disregard the law will be held accountable, and we are committed to using all our powers to hold them responsible.

 

The FDA has made it clear that it will work together with federal partners, including the Department of Justice, to take enforcement actions and seek permanent injunctions against illegal behavior.

 

This action is part of a comprehensive approach to coordinated enforcement by the FDA and other federal agencies. Last year, in a joint operation at Los Angeles International Airport, the U.S. Customs and Border Protection seized over $18 million worth of illegal e-cigarettes. In addition, the FDA has issued 678 warning letters to companies suspected of manufacturing, selling, and/or distributing unauthorized novel tobacco products, issued over 550 warning letters to retailers, filed civil penalty complaints against 57 manufacturers and 140 retailers for selling unauthorized tobacco products.

 

The eight manufacturers who received permanent injunctions are as follows:

 

Boosted LLC and Owner Cory Vigil Receive Permanent Injunction from FDA and DOJ

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

2Firsts Data|China’s Vape-Related Exports Rose 3.3% in August 2026 as UK Shipments Jumped 51.4% and U.S. Exports Fell 12.4%
2Firsts Data|China’s Vape-Related Exports Rose 3.3% in August 2026 as UK Shipments Jumped 51.4% and U.S. Exports Fell 12.4%
China exported $979 million of vape-related products in August 2026, up 3.3% from a year earlier but down 6.4% from July. The UK replaced the U.S. as the main source of growth: UK-bound shipments jumped 51.4% to a 2026 high of $177 million, while exports to the U.S. fell 12.4% to $339 million. Shipments to markets outside the U.S. increased 14.2%, broadening growth beyond the market that had driven July’s rebound.
News
Sep.23 by 2Firsts Perspectives
Japan Survey Finds 49.5% Would Cut Tobacco Use if Prices Rise, 64.6% Show Interest in Nicotine-Free Alternatives
Japan Survey Finds 49.5% Would Cut Tobacco Use if Prices Rise, 64.6% Show Interest in Nicotine-Free Alternatives
A September online survey commissioned by Japanese smoking-accessories company Lightec found that 49.5% of respondents would consider reducing tobacco use if prices rose further, while 25.1% would consider switching to cheaper brands and 14.5% would consider using or combining alternatives such as vapes and nicotine-free herbal sticks. Another 64.6% expressed some level of interest in such alternatives. The survey covered 1,088 respondents aged 20 to 70 and was conducted by a company that sells NICOLESS nicotine-free vaping and herbal-stick products, meaning its findings should not be treated as representative of Japan's smoking population.
DATA
Oct.12
New York City Opens Lottery for 55 Vape Retail License Slots Across 23 Community Districts, Including 28 in Brooklyn
New York City Opens Lottery for 55 Vape Retail License Slots Across 23 Community Districts, Including 28 in Brooklyn
New York City's Department of Consumer and Worker Protection (DCWP) opened applications on November 2, 2026, for a lottery covering tobacco and electronic cigarette retail dealer licenses, with a deadline of 5 p.m. New York local time on November 30. According to the city's October 1 notice, 55 electronic cigarette retail license slots are available across 23 community districts, including 28 in Brooklyn, alongside 322 tobacco retail license slots across 41 districts. Businesses must enter the lottery and, if invited, complete licensing requirements within 65 days. New York City continues to restrict e-cigarette retail sales to tobacco-flavored or unflavored products, while city retail licenses do not replace FDA product marketing authorization.
Market
Nov.04
Zhang Xiaotang Appointed Deputy Director of China’s Tobacco Regulator, Adding Another Finance-Background Official to Top Leadership
Zhang Xiaotang Appointed Deputy Director of China’s Tobacco Regulator, Adding Another Finance-Background Official to Top Leadership
China’s State Council has appointed Zhang Xiaotang as deputy director of the State Tobacco Monopoly Administration, with the regulator’s official website now listing him as a Party leadership group member and deputy director. Zhang previously led Hebei China Tobacco and earlier headed the STMA’s finance and audit department. His appointment follows the elevation earlier this year of former tax official Yao Laiying to head the STMA, adding another senior official with a strong fiscal or financial-management background to China Tobacco’s top leadership in 2026.
News
Sep.20
U.S. Rep. Krishnamoorthi Questions FDA Over Planned PMTA Rewrite, Seeks Communications With Altria and Reynolds
U.S. Rep. Krishnamoorthi Questions FDA Over Planned PMTA Rewrite, Seeks Communications With Altria and Reynolds
U.S. Rep. Raja Krishnamoorthi on Oct. 6 questioned the FDA over its plan to reassess and potentially replace the 2021 PMTA regulatory framework, asking the agency to identify provisions it may change or eliminate, state whether current scientific evidentiary standards will be maintained, and disclose communications with Altria, Reynolds and other parties challenging the rule. Krishnamoorthi led a congressional investigation into JUUL and youth vaping in 2019 and has since remained active on e-cigarette regulation and enforcement.
Regulations
Oct.08
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22